Synlogic, Inc. (NASDAQ:SYBX) headquartered in Cambridge, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.synlogictx.com
Earnings Expectation
Synlogic, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, SYBX to report 3Q20 loss of $ 0.47 per share. For the full year, analysts anticipate top line of $ 0.98 million, while looking forward to loss of $ 1.84 per share bottom line.
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
